Etanercept, a tumor necrosis factor (TNF) receptor alpha antagonist is licensed for the treatment in patients affected by polyarticular juvenile idiopathic arthritis, who do not tolerate or had an inadequate response to methotrexate. Infections related to immunosuppression by etanercept are of major concern. We report on a 17-year-old boy with enthesitis-related arthritis who developed a major infection of an urachal cyst 18 months after initiation of etanercept therapy, which required surgery. The urachus had not been symptomatic before.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00296-008-0521-z | DOI Listing |
Publication Analysis
Top Keywords
infection urachal
8
urachal cyst
8
etanercept therapy
8
juvenile idiopathic
8
idiopathic arthritis
8
etanercept
4
cyst etanercept
4
therapy juvenile
4
arthritis etanercept
4
etanercept tumor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!